Table 1.
Patient demographics and characteristics at core baseline for patients who continued on their randomized therapy in the extension phase
| Demographic variable | Pasireotide LAR (n = 74) | Octreotide LAR (n = 46) |
|---|---|---|
| Age, years | n = 74 | n = 46 |
| Median (range) | 46.5 (22 − 71) | 45.0 (24 − 70) |
| Sex, n (%) | ||
| Female | 38 (51.4) | 26 (56.5) |
| Male | 36 (48.6) | 20 (43.5) |
| Race, n (%) | ||
| Caucasian | 41 (55.4) | 28 (60.9) |
| Black | 0 | 1 (2.2) |
| Asian | 21 (28.4) | 9 (19.6) |
| Native American | 3 (4.1) | 0 |
| Other | 9 (12.2) | 8 (17.4) |
| Previous surgery, n (%) | 37 (50.0) | 20 (43.5) |
| GH level, μg/L | n = 70 | n = 45 |
| Mean (SD) | 14.4 (21.4) | 11.3 (12.7) |
| Median (range) | 6.9 (0.8–114.6) | 6.5 (1.4–64.1) |
| IGF-1 level, × ULN | n = 74 | n = 46 |
| Mean (SD) | 2.6 (1.2) | 2.5 (1.1) |
| Median (range) | 2.4 (0.9–5.9) | 2.4 (0.9–6.5) |
| Tumor volume, mm3 | n = 71 | n = 43 |
| Mean (SD) | 1,981 (4,515) | 2,429 (4,936) |
| Median (range) | 646 (0–35,095) | 772 (53–25,473) |